Dedicated to Research Since 1993

Global Engineered T Cells Market by Type (Tumor Infiltrating Lymphocytes, T Cell Receptor {TCR}, Chimeric Antigen Receptor (CAR)) by Application (Lung Cancer, Breast Cancer, Colorectal Cancer, Melanoma, Leukemia) – Business Overview, Analysis and Industry Forecast 2017-2023

 Healthcare and Pharmaceuticals

Report Overview

Global Engineered T Cells Market was valued at USD XX billion in the year 2017. Global Engineered T Cells market is further estimated to grow at a CAGR of XX % from 2018 to reach USD XX billion by the year 2023.

In the Global Engineered T Cells Market, by region North America holds the highest market share in 2017 and is also market is considered as the fastest growing market in the forecasted period owing to their market demands. At a country level, the U.S is projected to grow strongly in the coming years due to high-end aerospace applications. The presence of well-established biopharmaceutical companies & advanced biotech research facilities is projected to support the growth of engineered T cells market


            Increase in government expenditure for the healthcare sector


            Risk of allergic reaction and limitations of the engineered T cells treatment


            Increase in R&D in engineered T cells


            High cost of engineered T cells treatment

The engineered T cells market is segmented based on type, application, end user, and geography. On the basis of type, the market is categorized into tumor infiltrating lymphocytes, T cell receptor {TCR}, and chimeric antigen receptor (CAR). Of these the chimeric antigen receptor cells accounts for the highest revenue, due to increased applications.

Autolus Limited, Bellicum Pharmaceuticals, Inc., Cells Medica, Elli Lilly and Company, Gilead Sciences, Inc., Juno Therapeutics, Novartis AG, Oxford Biomedica, Pfizer Inc., and Precision Bioscience are some of the key players in the Global Engineered T Cells market.

Key Benefits for Stakeholders

Engineered T Cells Manufacturers and raw material suppliers

Healthcare institutions and professionals

Research and Consulting Organization

End-use industries

Investment research firms

By Type

Tumor Infiltrating Lymphocytes

T Cell Receptor {TCR}

Chimeric Antigen Receptor (CAR)

By Application

Lung Cancer

Breast Cancer

Colorectal Cancer




By End User


Cancer Research Centers


By Region

North America




Key Market Players

Autolus Limited

Gilead Sciences, Inc.

Bellicum Pharmaceuticals, Inc.

Juno Therapeutics

Cells Medica

Novartis AG

Elli Lilly and Company

Oxford Biomedica

Pfizer Inc.

Precision Bioscience

 (A brief overview of 10 companies is also provided)

Research Methodology:

Genesis Market Insights follows in-depth Research Methodology focused on reducing deviation in the collected data. GMI offers the most precise evaluations and projection for the market numbers. GMI engages following Market Engineering techniques –

  1. Raw Market Data is collected and compared with the Existing in-house Data on a broad front.
  2. Both Bottom-Up and Top-Down approaches are analyzed for segmenting and estimating measurable aspects of the market.
  3. To avoid bias, we filter the collected data collected from authenticated sources.
  4. GMI has a well proven Statistical Modeling System for estimates and forecasts.
  5. Further, the report findings are validated with the Industry Expert Panel on face to face or telephonic interviews.
  6. Panelists are approached from Leading Enterprises across the value chain including manufacturers, suppliers, technology providers, domain experts and buyers so as to validate a thorough and balanced market overview.

Detailed customization is also available for you. Further, if the report listed above does not meet your key requirements. Our customized research report will analytically cover the required market information you need which will help you to plan your business decisions.

Table Of Content

1. Introduction

1.1 Market Vision

       1.1.1 Market Definition

       1.1.2 Market Scope

1.2 Limitations

1.3 Stakeholders

2. Research Methodology

2.1. Research Process

       2.1.1. Secondary Research

    Key Data from Secondary Research

       2.1.2. Primary Research

    Key Data from Primary Research

    Breakdowns of Primary Interviews

2.2. Market Size Estimation

       2.2.1. Bottom-Up Approach

       2.2.2. Top-Down Approach

       2.2.3. Annual Revenue Process

2.3. Data Triangulation 

2.4. Research Assumptions 

       2.4.1. Assumption

3. Executive Summary

4. Market Overview

4.1. Introduction

4.2. Drivers

4.3. Restraints

4.4. Opportunities

4.5. Challenges

4.6. Regulations

4.7. Supply Chain/Value Chain Analysis

4.8. Patent & Standards

5. Industry Trends

5.1. Introduction

5.2. Porter’s Five Forces Analysis

       5.2.1. Threat of New Entrants

       5.2.2. Threat of Substitutes

       5.2.3. Bargaining Power of Buyers

       5.2.4. Bargaining Power of Suppliers

       5.2.5. Intensity of Competitive Rivalry

6. Engineered T Cells Market, By Type

6.1 Tumor Infiltrating Lymphocytes

6.2 T Cell Receptor {TCR}

6.3 Chimeric Antigen Receptor (CAR)

7. Engineered T Cells Market, By Application

7.1 Lung Cancer

7.2 Breast Cancer

7.3 Colorectal Cancer

7.4 Melanoma

7.5 Leukemia

7.6 Others

8. Engineered T Cells Market, End Users

8.1 Hospitals

8.2 Cancer Research Centers

8.3 Clinics

9. Geographical Analysis

9.1. Introduction

9.2. North America

       9.2.1. U.S.

       9.2.2. Canada

       9.2.3. Mexico

9.3. Europe

       9.3.1. U.K.

       9.3.2. Germany

       9.3.3. France

       9.3.4. RoE

9.4. Asia Pacific

       9.4.1. South Korea

       9.4.2. China

       9.4.3. Japan

       9.4.4. RoAPAC

9.5. RoW

       9.5.1. Latin America

       9.5.2. Middle East and Africa

10. Company Profiles

(Business Overview, Financial Overview, Product write Up, Recent Developments)

10.1 Autolus Limited

10.2 Gilead Sciences, Inc.

10.3 Bellicum Pharmaceuticals, Inc.

10.4 Juno Therapeutics

10.5 Cells Medica

10.6 Novartis AG

10.7 Elli Lilly and Company

10.8 Oxford Biomedica

10.9. Pfizer Inc.

10.10 Precision Bioscience

(A brief overview of 10 companies is also provided.)

11. Competitive Analysis

11.1. Introduction

11.2. Market Positioning of Key Players

11.3 Competitive Strategies Adopted by Leading Players

        11.3.1. Investments & Expansions

        11.3.2. New Product Launches

        11.3.3. Mergers & Acquisitions

        11.3.4. Agreements, Joint Ventures, and Partnerships

12. Appendix

12.1. Questionnaire

12.2. Available Customizations 

12.3. Upcoming Events (Trade Fair, Exhibitions, Conferences)

* The list of tables and figures will be provided in the sample report.


No Content Available.



Related Reports